# Liquiritigenin **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/liquiritigenin **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-19 **Evidence Score:** 4 / 10 **Category:** Compound **Also Known As:** (2S)-4',7-dihydroxyflavanone, 7,4'-dihydroxyflavanone, LQ, Licorice flavanone, Gan Cao flavonoid, Glycyrrhiza flavanone ## Overview Liquiritigenin is a flavanone compound found in licorice root that acts as a selective estrogen receptor beta (ERβ) agonist with an EC50 of 36.5 nM. This selective mechanism provides estrogenic benefits without stimulating proliferative pathways associated with breast cancer risk. ## Health Benefits • Selective estrogen receptor beta (ERβ) activation with EC50 of 36.5 nM, promoting beneficial estrogenic effects without ERα proliferation (preclinical evidence only) • Non-proliferative estrogenic activity that doesn't stimulate breast cancer cell growth in MCF-7 cells (in vitro studies) • Potential age-related disease applications through ERβ-specific transcription (theoretical based on mechanism studies) • Distinct from harmful estrogenic effects by avoiding c-myc and cyclin D1 gene activation (cellular studies) • Possible [anti-inflammatory](/ingredients/condition/inflammation) properties as part of licorice's bioactive profile (traditional use inference, no direct clinical evidence) ## Mechanism of Action Liquiritigenin selectively binds to and activates estrogen receptor beta (ERβ) with high affinity (EC50 of 36.5 nM) while showing minimal activity at estrogen receptor alpha (ERα). This selective activation promotes beneficial estrogenic signaling pathways including bone protection and [cardiovascular](/ingredients/condition/heart-health) benefits without triggering proliferative responses in breast and endometrial tissues. The compound demonstrates non-proliferative estrogenic activity in MCF-7 breast cancer cells, indicating safer estrogenic modulation. ## Clinical Summary Current evidence for liquiritigenin consists primarily of preclinical in vitro and animal studies, with limited human clinical data available. Laboratory studies demonstrate selective ERβ activation at nanomolar concentrations and non-proliferative effects in breast cancer cell lines. Animal studies suggest potential benefits for menopausal symptoms and [bone health](/ingredients/condition/bone-health) through selective estrogen receptor modulation. Human clinical trials are needed to establish therapeutic efficacy, optimal dosing, and safety profiles in target populations. ## Nutritional Profile Liquiritigenin is a flavanone aglycone compound (molecular weight: 256.25 g/mol) derived primarily from licorice root (Glycyrrhiza species), not a conventional nutrient source with macronutrient or micronutrient content. As a pure bioactive compound, it contains no protein, fat, fiber, or vitamins. Bioactive concentration: found in licorice root at approximately 0.1–0.5% dry weight depending on species and extraction method. Oral bioavailability is limited due to first-pass [metabolism](/ingredients/condition/weight-management) and poor aqueous solubility; it undergoes intestinal glucuronidation and sulfation, reducing systemic exposure. Gut microbiota can convert the glycoside liquiritin to liquiritigenin via beta-glucosidase activity, meaning colonic conversion is a meaningful bioavailability pathway. Peak plasma concentrations in animal models range from 50–200 ng/mL following oral dosing at 10–50 mg/kg. No established dietary reference intake or therapeutic dose has been validated in human clinical trials. ## Dosage & Preparation No clinically studied dosage ranges for liquiritigenin in humans have been established. Preclinical studies use purified compounds, but human dosing, standardization details, and recommended forms (extract, powder) are not available. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Safety data for liquiritigenin supplementation in humans is limited due to lack of comprehensive clinical trials. As an estrogenic compound, it may theoretically interact with hormone replacement therapy, birth control pills, and hormone-sensitive medications. Individuals with hormone-sensitive conditions including breast, ovarian, or endometrial cancers should exercise caution. Pregnancy and breastfeeding safety has not been established, and use should be avoided during these periods without medical supervision. ## Scientific Research No human clinical trials, randomized controlled trials, or meta-analyses specifically on liquiritigenin were identified in the available research. Current evidence is limited to preclinical studies examining its ERβ selectivity and cellular mechanisms, with no PMIDs available for human studies. ## Historical & Cultural Context While liquiritigenin itself lacks documented standalone traditional use, it occurs naturally in Glycyrrhiza species that have been used in Traditional Chinese Medicine for various ailments. The compound is found in licorice roots alongside related flavonoids like isoliquiritigenin and liquiritin. ## Synergistic Combinations Liquiritigenin pairs well with genistein (soy isoflavone), which also demonstrates ERβ selectivity; co-administration may produce additive ERβ transcriptional activation while maintaining low ERα stimulation, potentially relevant for menopausal symptom management without proliferative risk. Piperine (black pepper extract, 5–20 mg) inhibits glucuronidation enzymes (UGT1A family) that rapidly metabolize liquiritigenin, meaningfully enhancing its oral bioavailability — a mechanism mirroring its well-documented enhancement of curcumin absorption. Resveratrol complements liquiritigenin through overlapping SIRT1 activation and ERβ-mediated [neuroprotective](/ingredients/condition/cognitive) pathways, potentially offering additive effects in age-related cognitive applications; additionally, quercetin shares flavonoid [metabolism](/ingredients/condition/weight-management) pathways and may competitively reduce liquiritigenin's conjugation burden in the gut, modestly prolonging its active circulating half-life. ## Frequently Asked Questions ### What is the difference between liquiritigenin and other phytoestrogens? Liquiritigenin uniquely demonstrates selective estrogen receptor beta activation with an EC50 of 36.5 nM, unlike many phytoestrogens that activate both ERα and ERβ receptors. This selectivity potentially provides estrogenic benefits without the proliferative risks associated with ERα activation in breast and endometrial tissues. ### How much liquiritigenin is found in licorice root? Liquiritigenin content in licorice root varies significantly based on species and extraction methods, typically ranging from 0.1-2% by weight in Glycyrrhiza species. Standardized extracts may concentrate liquiritigenin to higher percentages, but specific dosing for therapeutic effects has not been established in human studies. ### Can liquiritigenin help with menopausal symptoms? Preclinical studies suggest liquiritigenin may help menopausal symptoms through selective ERβ activation, which could provide estrogenic benefits without proliferative risks. However, human clinical trials specifically testing liquiritigenin for menopausal symptoms are lacking, making therapeutic claims premature. ### Does liquiritigenin interact with tamoxifen or other cancer medications? While no specific interaction studies exist, liquiritigenin's estrogenic activity could theoretically interfere with selective estrogen receptor modulators like tamoxifen. Cancer patients should consult oncologists before using liquiritigenin supplements due to potential hormonal interactions and lack of safety data. ### Is liquiritigenin safe for people with hormone-sensitive cancers? Liquiritigenin's safety in hormone-sensitive cancers is unknown and concerning given its estrogenic activity, despite selective ERβ targeting. While in vitro studies show non-proliferative effects in MCF-7 breast cancer cells, comprehensive safety studies in cancer patients are absent, warranting extreme caution. ### What is the current evidence quality for liquiritigenin's health benefits in humans? Most evidence for liquiritigenin comes from in vitro and preclinical animal studies showing selective ERβ activation; clinical trials in humans remain limited. The non-proliferative estrogenic activity demonstrated in laboratory settings has not yet been confirmed through large-scale human studies. While the mechanistic research is promising, supplement claims should be viewed as preliminary until robust clinical data emerges. ### How is liquiritigenin bioavailability affected by food or supplement formulation? As a flavonoid, liquiritigenin's absorption may be enhanced when consumed with foods containing fat or taken with meals that support lipid absorption. The bioavailability of liquiritigenin from whole licorice root extracts may differ from isolated compound supplements due to the presence of other phytochemicals that can modulate absorption. Standardized extracts typically provide more consistent liquiritigenin levels compared to whole plant preparations, though comparative bioavailability studies in humans are limited. ### Who might benefit most from liquiritigenin supplementation based on its ERβ-selective mechanism? Individuals seeking selective estrogenic effects without proliferative stimulation—such as those with age-related concerns or postmenopausal health—are the theoretical target population based on ERβ-specific activation. However, this benefit remains theoretical and is not yet supported by clinical evidence in humans. Anyone considering liquiritigenin supplementation should consult a healthcare provider, particularly those with estrogen-dependent conditions or taking hormone-related medications. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*